Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Visceral disease site to predict clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA): Results of the Italian compassionate use named patient program (NPP)., Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO),
DOI: 10.1200/jco.2015.33.15_suppl.e16045.
You can read the full text:

Read

Contributors

The following have contributed to this page